Diabetes

Study explores dose ranges for efpeglenatide in early T2DM

(HealthDay)—Efpeglenatide once weekly leads to dose-dependent reductions in glucose and body weight in patients with early type 2 diabetes, according to a phase 2 study published online July 18 in Diabetes Care.

Diabetes

FDA approves first noninjection glucagon therapy

(HealthDay)—The U.S. Food and Drug Administration has approved the first noninjection glucagon therapy for emergency treatment of severe hypoglycemia, the agency announced late yesterday.

Medical research

New discovery could lead to improved blood sugar level control

Many diabetes patients do not only have problems with their insulin, but also with the release of the hormone glucagon. Researchers at Uppsala University have now discovered a regulation mechanism which could provide an opportunity ...

Cardiology

Certain SGLT2 inhibitors, GLP-1 RAs for T2DM also cut CV risk

(HealthDay)—Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk ...

Medical research

Uncovering the whole story in diabetes

More than 400 million people worldwide suffer from type 2 diabetes, a disease characterised by increased blood glucose levels, because the body's normal way of controlling insulin release breaks down.

Diabetes

Improved rescue kits for people with diabetes, hypoglycemia

Being with someone who has diabetes and needs immediate care to avoid a coma can be a frightening situation. Even worse, current products and injection kits to help in those emergencies can be complicated to use.

page 3 from 7